Frequency of RSV infections in preterm infants after monoclonal antibody prophylaxis

Authors

  • NeÅ¡ad Hotic
  • Fahrija Skokic
  • Amela Selimović
  • Almira Ćosićkić
  • Evlijana Zulić

DOI:

https://doi.org/10.5457/ams.v45i1-2.443

Abstract

The aim: to investigate the frequency of RSV infections in preterm infants with 33-35 gestational weeks after the use of monoclonal antibody prophylaxis

Methods: The study involved preterm born children (33-35 gestation weeks) 1 to 5 years old who received palivizumab for prophylaxis of respiratory infections caused by RSV. 108 patients met inclusion criteria and were hospitalized at the University Clinical Center Tuzla, Clinic for Children's Diseases, Bosnia and Herzegovina in the period 26 September, 2013- 22 July, 2014. Detection of virus in serum of infected children was conducted at the Institute for Diagnostic, University Clinical Center Tuzla.

Results: During the time period of investigation there were 4095 live born infants, of which 6.7% (N 274) were preterm, of which 74.8% infants were between 33-35 weeks of gestation. Out of 205 preterm infants with gestational age 33-35 weeks, palivizumab immunoprophylaxis for RSV infections received 108 (52.6% ) infants. Out of a total of 108 preterm infants with gestational age 33-35 weeks who received palivizumab immunoprophylaxis, RSV infection developed in 7 infants (6.5%). All the children with the RSV infection had at least one comorbidity, and the diagnosis confirmed were bronchopulmonary dysplasia/chronic pulmonary disease and congenital heart anomalies.

Conlusion: Our data suggest that palivizumab prophylaxis to late preterm infants results in lower incidence of RSV infectiones in analised group of infants.

 

Downloads

Published

2018-02-02

Issue

Vol. 45 No. 1-2 (2016): 1-2

Section

Original papers

License

Copyright transfer

The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.